Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400652 | 1.00 | OPRK1 (0.46) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL4397929 | 0.91 | POLB (0.40) | OPRK1POLBEPHX2MAPTALDH1A1 | |
| SCHEMBL13643851 | 0.89 | OPRK1 (0.49) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL4397934 | 0.88 | OPRK1 (0.45) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL13880959 | 0.88 | POLB (0.46) | POLBMAPTTSHRALDH1A1MEN1 | |
| SCHEMBL4400850 | 0.88 | POLB (0.49) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL13643840 | 0.87 | OPRK1 (0.52) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL13643871 | 0.87 | OPRK1 (0.52) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL13643847 | 0.87 | OPRK1 (0.45) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL18249449 | 0.86 | POLB (0.49) | OPRK1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793928-B1 | PROCESS FOR PURIFYING A SAMPLE OF H38C2 ANTIBODY | PFIZER (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| WO-2013093720-A2 | ANTI-DIABETIC COMPOUNDS | PFIZER INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| WO-2012059873-A2 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LTD. (IE) | 2012-05-10 | — | — | WO | disclosed |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008081418-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282279-A1 | Anti-Diabetic Compounds | GLP1R, FGF2, FGFR1 | OPRK1 4623/4885CA12 1471/4885CA1 3262/4885 |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | OPRK1 1995/4885CA12 2579/4885CA1 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.